Rescue Hearing’s initial gene therapy product will target a genetic mutation known to cause progressive hearing loss which eventually leads to deafness.
Rescue Hearing is thrilled to announce its entry into a Worldwide Exclusive License Agreement with the innovative company, Myrtelle! This exciting collaboration is set to take place in Q3 2022 and promises to bring cutting-edge solutions to the world of hearing care.
RHI has assembled a team of visionary, internationally recognized physicians, scientists, and bioengineers who share a common passion for developing therapies for humans suffering from hearing loss. The team is developing therapeutic and diagnostic platforms that will address the most difficult hearing loss indications.
Chief Scientific Officer
Scientific Advisor
Scientific Advisor
Targets individuals born with progressive hearing loss
RHI100 is a multi-billion dollar asset (Peak revenue 2032)
RHI200 is currently in the pre-IND studies phase